Canada's Research-Based Pharmaceutical Companies (Rx&D) are claiming victory following a Federal Court of Appeal ruling upholding a key clause in Canada's intellectual property regime. The ruling upholds a 2009 decision by the federal Court of Canada which dismissed a challenge by the generic drug industry to Food and Drug Regulations providing patent holders eight years of data protection. While applauding the decision for providing clarity and fairness, Rx&D stated that data protection must be extended "to match the standards set by our major trading partners"....